GlassScriptPhysician profile
Noelle L Bertelson
NPI 1134386154
$4,074.07
in general payments reported to CMS, 2019-2025
15 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $1,230 · 2021: $89.45 · 2022: $111 · 2023: $1,206 · 2024: $386 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895 · Consulting Fee: $813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.59 |
| Consulting Fee | $813.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $1,508.04 | 2019-2020 | |
| Medtronic, INC. | $813.00 | 2023 | |
| Intuitive Surgical, INC. | $339.49 | 2019-2024 | |
| Kerecis Limited | $285.26 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Axonics, INC. | $216.37 | 2022-2023 | Axonics |
| Takeda Pharmaceuticals U.S.A., INC. | $191.75 | 2023 | Entyvio |
| Davol INC. | $151.67 | 2019 | |
| Acell, INC. | $139.52 | 2019-2020 | |
| Erbe USA INC | $115.35 | 2025 | Vio3/Apc3/Erbjet2 |
| Smith+Nephew, INC. | $97.13 | 2019 | |
| Stryker Corporation | $96.28 | 2023 | Spy-Phi System |
| Integra Lifesciences Corporation | $76.76 | 2021 | |
| Baudax Bio INC. | $18.58 | 2020 | |
| Olympus America INC. | $12.69 | 2021 | |
| Boston Scientific Corporation | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noelle Bertelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.